A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Background Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase Ib study to assess the safety and tolera...
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
BMJ Publishing Group
2016-12-01
|
| Saila: | Journal for ImmunoTherapy of Cancer |
| Sarrera elektronikoa: | https://jitc.bmj.com/content/4/1/85.full |